BUCHANG PHARMA(SH:603858) Guo Ji Jin Rong Bao·2025-09-18 13:58Core Viewpoint - The company, Buchang Pharma, has announced a cash dividend of 0.39 yuan per share, totaling 411 million yuan, reflecting its commitment to shareholder returns and robust cash flow [1][2]. Dividend Trends - There is a noticeable trend of increasing cash dividends among pharmaceutical companies, with Buchang Pharma being the first to implement a mid-term dividend since its listing, aligning with regulatory encouragement for higher shareholder returns [2]. - The dividend of 0.39 yuan per share positions Buchang Pharma at an above-average level within the industry, with a dividend yield of 2.52%, which is higher than that of peers like WuXi AppTec and Dong-E E-Jiao [2]. Financial Performance Supporting Dividends - The company has adopted a strategy of simultaneous cash dividends and share buybacks, with cumulative dividends reaching 7.948 billion yuan and share buybacks totaling 1.744 billion yuan [3]. - Strong cash flow from operating activities supports the company's ability to distribute dividends while maintaining business growth [3]. - The company has contributed over 32 billion yuan in taxes, indicating a positive impact on local economies and reflecting its strong financial performance [3]. Corporate Governance and Market Position - Cash dividends serve as a reflection of corporate governance quality and help attract long-term investors, enhancing the company's market image [4]. - Buchang Pharma's commitment to stable dividends signals confidence in future growth and shareholder returns, especially as the pharmaceutical industry shifts towards innovation and research-driven models [4]. - The company aims to leverage artificial intelligence in traditional Chinese medicine innovation and expand into the biopharmaceutical sector, contributing to the high-quality development of the healthcare industry [4].